324 related articles for article (PubMed ID: 35469916)
21. Targeting gut microbiota for immunotherapy of diseases.
Yu YJ; Liu XD; Liao C; Yu R; Wang X; Li M; Wang Y
Arch Toxicol; 2024 May; ():. PubMed ID: 38722348
[TBL] [Abstract][Full Text] [Related]
22. The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer.
Naqash AR; Kihn-Alarcón AJ; Stavraka C; Kerrigan K; Maleki Vareki S; Pinato DJ; Puri S
Ann Transl Med; 2021 Jun; 9(12):1034. PubMed ID: 34277834
[TBL] [Abstract][Full Text] [Related]
23. Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody.
Murayama M; Hosonuma M; Kuramasu A; Kobayashi S; Sasaki A; Baba Y; Narikawa Y; Toyoda H; Isobe J; Funayama E; Tajima K; Sasaki A; Maruyama Y; Yamazaki Y; Shida M; Hamada K; Hirasawa Y; Tsurui T; Ariizumi H; Ishiguro T; Suzuki R; Ohkuma R; Kubota Y; Horiike A; Sambe T; Tsuji M; Wada S; Kobayashi S; Shimane T; Tsunoda T; Kobayashi H; Kiuchi Y; Yoshimura K
Sci Rep; 2024 May; 14(1):11325. PubMed ID: 38760458
[TBL] [Abstract][Full Text] [Related]
24. Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality.
Guillot N; Roméo B; Manesh SS; Milano G; Brest P; Zitvogel L; Hofman P; Mograbi B
Trends Mol Med; 2023 Nov; 29(11):897-911. PubMed ID: 37704493
[TBL] [Abstract][Full Text] [Related]
25. Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy.
Gomes S; Rodrigues AC; Pazienza V; Preto A
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982144
[TBL] [Abstract][Full Text] [Related]
26. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
[TBL] [Abstract][Full Text] [Related]
27. Microbial short-chain fatty acids: a strategy to tune adoptive T cell therapy.
Rangan P; Mondino A
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35882448
[TBL] [Abstract][Full Text] [Related]
28. Gut microbiome in modulating immune checkpoint inhibitors.
Li X; Zhang S; Guo G; Han J; Yu J
EBioMedicine; 2022 Aug; 82():104163. PubMed ID: 35841869
[TBL] [Abstract][Full Text] [Related]
29. Microbial metabolites and immunotherapy: Basic rationale and clinical indications.
Kovtonyuk LV; McCoy KD
Semin Immunol; 2023 May; 67():101755. PubMed ID: 36989542
[TBL] [Abstract][Full Text] [Related]
30. The potential role of short chain fatty acids improving
González-Brito A; Uribe-Herranz M
Front Immunol; 2023; 14():1083303. PubMed ID: 36742300
[TBL] [Abstract][Full Text] [Related]
31. The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
Roberto M; Carconi C; Cerreti M; Schipilliti FM; Botticelli A; Mazzuca F; Marchetti P
Front Immunol; 2021; 12():704942. PubMed ID: 34489956
[TBL] [Abstract][Full Text] [Related]
32. The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review.
Araji G; Maamari J; Ahmad FA; Zareef R; Chaftari P; Yeung SJ
J Immunother Precis Oncol; 2022 Feb; 5(1):13-25. PubMed ID: 35663831
[TBL] [Abstract][Full Text] [Related]
33. Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer.
Kang YB; Cai Y
World J Gastroenterol; 2021 Aug; 27(32):5362-5375. PubMed ID: 34539138
[TBL] [Abstract][Full Text] [Related]
34. Gut microbiome production of short-chain fatty acids and obesity in children.
Murugesan S; Nirmalkar K; Hoyo-Vadillo C; García-Espitia M; Ramírez-Sánchez D; García-Mena J
Eur J Clin Microbiol Infect Dis; 2018 Apr; 37(4):621-625. PubMed ID: 29196878
[TBL] [Abstract][Full Text] [Related]
35. Microbiome bacterial influencers of host immunity and response to immunotherapy.
Yousefi Y; Baines KJ; Maleki Vareki S
Cell Rep Med; 2024 Apr; 5(4):101487. PubMed ID: 38547865
[TBL] [Abstract][Full Text] [Related]
36. Complex interactions between the microbiome and cancer immune therapy.
Schwartz DJ; Rebeck ON; Dantas G
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):567-585. PubMed ID: 31526274
[TBL] [Abstract][Full Text] [Related]
37. Gut microbiota-derived short-chain fatty acids and hypertension: Mechanism and treatment.
Yang F; Chen H; Gao Y; An N; Li X; Pan X; Yang X; Tian L; Sun J; Xiong X; Xing Y
Biomed Pharmacother; 2020 Oct; 130():110503. PubMed ID: 34321175
[TBL] [Abstract][Full Text] [Related]
38. Dissecting Microbiome-Derived SCFAs in Prostate Cancer: Analyzing Gut Microbiota, Racial Disparities, and Epigenetic Mechanisms.
Miya TV; Marima R; Damane BP; Ledet EM; Dlamini Z
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627114
[TBL] [Abstract][Full Text] [Related]
39. Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy.
Kang X; Lau HC; Yu J
Cell Rep Med; 2024 Apr; 5(4):101478. PubMed ID: 38631285
[TBL] [Abstract][Full Text] [Related]
40. The role of short-chain fatty acids in kidney injury induced by gut-derived inflammatory response.
Huang W; Zhou L; Guo H; Xu Y; Xu Y
Metabolism; 2017 Mar; 68():20-30. PubMed ID: 28183450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
